Новости за 12.07.2022

Despite 22 years to address the issues about patient safety revealed by To Err Is Human, iatrogenic injury remains an important cause of morbidity and mortality among hospitalized patients. These adverse outcomes do not result from physicians and other clinicians intentionally harming patients, but reflect systematic failures, including insufficient investment in research and metrics, lack of safety technology innovations, limited infrastructure to deliver high-quality care, and inconsistent adherence to clinical practice guidelines.

Among patients with major depressive disorder (MDD), less than 40% achieve clinical remission after an initial treatment with an antidepressant. For those who do not improve after 2 or more antidepressant treatment trials (ie, treatment-resistant depression), the rates of remission are less than 20%. Because each of these failed treatments translates to several months of prolonged illness, a series of multiple ineffective treatments contributes to the substantial disability and morbidity associated with MDD... Читать дальше...

As monkeypox cases increased in the US and abroad, a report from the CDC’s Advisory Committee on Immunization Practices (ACIP) outlined data supporting the November 2021 decision to recommend JYNNEOS, a newer vaccine against monkeypox and smallpox, for individuals at risk of occupational exposure.

Growing melatonin use may have contributed to a 530% increase in annual pediatric melatonin ingestions—from 8337 in 2012 to 52 563 in 2021—reported to the American Association of Poison Control Centers’ National Poison Data System, according to a CDC report.

Great reforms are seldom accomplished over night. They are usually the outcome of a slow but unfailing evolution due to prolonged educational effort, sometimes coupled with the vigorous enforcement of new measures. By reason of the gradual appearance of the changes brought about, evidence of actual reforms is often difficult to secure when it is sought at too frequent intervals. This is likely to lead to discouragement at times, unless the searcher takes occasion to let longer periods of efforts... Читать дальше...

The Original Investigation titled “Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial,” published May 3, 2022, was corrected to fix 2 data errors in Table 1: the denominator for race and ethnicity data in the usual care group and the percentage of patients with BMI ≥30 in the self-monitoring group. This article was corrected online.

The Original Investigation titled “Effects of Liberal vs Restrictive Transfusion Thresholds on Survival and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants: The ETTNO Randomized Clinical Trial,” published in the August 11, 2020, issue of JAMA, has been corrected to include the nonauthor collaborator names in a supplement.

An implantable, dissolving “smart” cardiac pacemaker has been designed for patients who need temporary pacing after cardiovascular surgery, according to a report in Science. The device could eliminate prolonged hospitalizations and infection risks associated with temporary pacemakers that keep patients tethered to external monitors and power packs with percutaneous lead wires.

Metastatic pancreatic cancer tumors shrank by nearly three-quarters 6 months after a patient received a single infusion of engineered autologous T cells targeting a common KRAS gene variant, according to a case study published in the New England Journal of Medicine.

Treatment with 2 monoclonal antibodies completely suppressed HIV for about 40 weeks in patients who participated in a small phase 1 trial. The findings, reported in Nature, suggest that future antibody therapies may offer effective HIV treatment for extended periods without antiretroviral therapy (ART).

There is a growing demand for medical scribes, and for good reason. Read on to discover how and why to become a medical scribe in our complete guide.

Roundworms are the cornerstone of scientific discoveries that have helped shape how we understand human disease and treatment. BioSpace takes a look at advances in C. elegans research.

Aldeyra Therapeutics announced results from a crossover clinical trial, showing that its drug candidate reproxalap was effective in improving ocular redness and tear production in patients with dry eye disease.

Partnering is an important way to grow a business, and John Sharkey, Ph.D., newly-hired VP of business development for GeoVax, is well-positioned to identify strong partners.

Genentech has exercised the second option in its potentially $1.7 billion agreement with Bicycle Therapeutics, triggering a $10 million payment.

Annexon and Pliant Therapeutics both made efforts to secure additional financing to support their R&D endeavors.

Nanoscope Therapeutics will make two presentations at the 2022 ASRS meeting on their gene therapy programs to treat degenerative retinal diseases, retinitis pigmentosa and Stargardt disease.

Discover how Eppendorf OEM worked with the market leader in laboratory automation to develop a win-win business model and 25-year partnership.

Moderna has dosed its first participant in a Phase I clinical trial of mRNA-1215, a vaccine designed to fight the Nipah virus (NiV), a virus contracted in humans through animals.

Verve Therapeutics dosed its first patient with VERVE-101, a one-time treatment that aims to permanently lower low-density lipoprotein (LDL) cholesterol in patients and prevent heart disease.

Backed by biopharma royalty, Areteia Therapeutics will focus on developing an old molecule for a very prevalent disease - asthma.

Epic Bio aims to transform genetic medicine by developing a new class of drugs that target the epigenome to alter gene expression.

NTT Ltd. Japan Corporation, Mitsui & Co., Ltd., PC Landing Corp, and JA Mitsui Leasing, Ltd. today announced the launch of a new company, Seren Juno Network Co., Ltd. (“Seren”) which has been founded to construct and operate “JUNO”, the new and largest trans-Pacific submarine cable system (providing the maximum capacity of 350Tbps) that will run between Japan and the US. According to leading telecommunications industry analyst firm…

read more on TotalTele.com »

This week, the Italian Navy have announced a new partnership with Telecom Italia’s submarine cable subsidiary, Sparkle, pledging to jointly improve the protection of national subsea infrastructure.  As part of the partnership, the duo plans to work together on shared operating procedures and potentially joint reconnaissance and monitoring activities in the areas surrounding Sparkle&rsquo…

read more on TotalTele.com »

Back in March, Orange Spain and MásMóvil announced their intention to merge, forming a 50:50 joint venture with an enterprise value of roughly €20 billion.  The deal would create a converged operator with around 7.1 million fixed line customers and 20.2 mobile customers, as well as 1.5 million TV customers.  Orange’s tower company, TOTEM, would notably be excluded from the merger…

read more on TotalTele.com »